Literature DB >> 14716221

Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension.

Emilio Kuschnir1, Mario Bendersky, Jorge Resk, Maria Silva Pañart, Luiz Guzman, Yankel Plotquin, Guido Grassi, Giuseppe Mancia, Gilbert Wagener.   

Abstract

Most hypertensive patients require more than one medication to effectively control elevated blood pressure (BP) values. This multicenter, randomized, double-blind study was aimed at testing the efficacy and safety of the combination of low-dose nifedipine GITS 20 mg/ losartan 50 mg compared with either monotherapy in patients with grade 1 to 3 hypertension over an eight-week period. Of 352 patients enrolled in the study, 300 were randomized. All the three treatments lowered elevated BP without clinically relevant changes in heart rate. All the three treatments lowered mean 24-hour diastolic BP: nifedipine GITS/losartan -10.6 mm Hg, losartan -5.4 mm Hg, nifedipine GITS 20 mg -8.0 mm Hg. There was a statistically significant difference of diastolic BP change between patients receiving losartan compared with those receiving combination treatment (P < 0.05). Diastolic BP trough-to-peak ratio and smoothness index were highest in the patient group receiving combination therapy (70%). Nifedipine GITS monotherapy had the highest systolic BP trough-to-peak ratio of all treatment arms (78%) and higher diastolic BP trough-to-peak ratio and smoothness index than losartan monotherapy. All treatments were safe. These data provide evidence that in hypertensive patients combination of nifedipine GITS 20 mg and losartan 50 mg improves control of systolic and diastolic BP compared with either monotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716221     DOI: 10.1097/00005344-200402000-00021

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.

Authors:  Harikrishna Makani; Sripal Bangalore; Azhar Supariwala; Jorge Romero; Edgar Argulian; Franz H Messerli
Journal:  Eur Heart J       Date:  2013-08-21       Impact factor: 29.983

Review 2.  Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Authors:  Katherine F Croom; Keri Wellington
Journal:  Drugs       Date:  2006       Impact factor: 11.431

Review 3.  Benefits of once-daily therapies in the treatment of hypertension.

Authors:  John M Flack; Samar A Nasser
Journal:  Vasc Health Risk Manag       Date:  2011-12-21

Review 4.  Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring.

Authors:  Sverre E Kjeldsen; Tonje A Aksnes; Luis M Ruilope
Journal:  Drugs R D       Date:  2014-06

5.  Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results.

Authors:  Sverre E Kjeldsen; Domenic Sica; Hermann Haller; Gloria Cha; Blas Gil-Extremera; Peter Harvey; Frank Heyvaert; Andrew J Lewin; Giuseppe Villa; Giuseppe Mancia
Journal:  J Hypertens       Date:  2014-12       Impact factor: 4.844

6.  Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis.

Authors:  Ling Liang; Janice Y Kung; Bradley Mitchelmore; Andrew Cave; Hoan Linh Banh
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-03-02       Impact factor: 2.885

Review 7.  Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk.

Authors:  H Haller
Journal:  Int J Clin Pract       Date:  2008-03-17       Impact factor: 2.503

8.  Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses.

Authors:  Sverre E Kjeldsen; Gloria Cha; Giuseppe Villa; Giuseppe Mancia
Journal:  J Clin Pharmacol       Date:  2016-03-07       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.